definiens: or means two or more corporations if the relationship between them is one in which one of them is a subsidiary of the other, or both are subsidiaries of the same corporation, or 50 % or more of the voting shares of each of them is owned or controlled by the same person, corporation or other legal entity ; ( b ) means this license agreement ; ( c ) is defined in Article 6.1 ; ( d ) means a report in the form referred to in Article 12 ; ( e ) means Microfluidic devices, instrumentation, methods, and other items specifically for the combination of : ( i ) the analysis of antibodies expressed by single cells for the purpose of identifying, screening, selecting or producing antibodies, followed by ( ii ) the genetic analysis of single cells for the purpose of identifying, screening, selecting or producing antibodies ; 2 ( f ) means substances or products of cells such as proteins or antibodies that are discovered or generated using the Technology or Improvements ; ( g ) means all information, regardless of its form : ( i ) disclosed by UBC to the Licensee and designated by UBC as confidential, whether orally or in writing, including without limitation all information and documents related to the Technology or any Imp rovements ( including all derived analyses and conclusions ) and the terms and conditions of this Agreement ; or ( ii ) disclosed by the Licensee to UBC and which is clearly identified in writing as, except that does not include information : ( iii ) possessed by the recipient ( the ) before receipt from the disclosing party ( the ), other than through prior disclosure by the Discloser, as evidenced by t he Recipient ’s business records ; ( iv ) published or available to the general public otherwise than through a breach of this Agreement ; ( v ) obtained by the Recipient from a third party with a valid right to disclose it, provided that the third party is not under a confidentiality obligation to the Discloser ; or ( vi ) independently developed by employees, agents or consultants of the Recip ient who had no knowledge of or access to the Discloser ’s information as evidenced by the Recipient ’s business records ; ( h ) means populations of 100 or fewer single cells ; ( i ) means collectively the rights in and to any and all inventions which are disclosed in the patent applications identified in Schedule, including : ( i ) counterparts, continuations, divisionals, continuing prosecution applications, and requests for continued examinations, extensions, term restorations, renewals, reissues, re -examinations, or substitutions thereof ; ( ii ) corresponding international patent applications ; ( iii ) corresponding foreign patent applications, including supplementary protection certificates and other administrative protections ; and ( iv ) international and foreign counterpart patents resulting therefrom, all of which will be deemed added, from tim e to time, to Schedule ; ( j ) means the Core Patents and any directly related knowledge, know -how and/or technique or techniques developed before the Start Date by the Investigator while employed at UBC ; ( k ) [ * * * ] ; ( l ) means use of the inventions disclosed and/or claimed in the Digital PCR Patents in the field of Microfluidics ; [ * * * ] Certain information in this document has been omitted from this exhibit because it is both ( i ) not material and ( ii ) would be competitively harmful if publicly disclosed